Navigation Links
Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:5/21/2013

ORLANDO, Fla., May 21, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) today announced primary efficacy and safety results from the global Phase 3 PROMISE study demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 79 percent of treatment-experienced genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis, when administered once daily with pegylated interferon and ribavirin.

In the study, 37 percent of patients receiving placebo plus pegylated interferon and ribavirin achieved SVR12. In the simeprevir arm, on-treatment failure rates were 3 percent and relapse rates were 19 percent, compared to 27 percent and 48 percent in the placebo arm. All patients had previously relapsed following pegylated interferon-based therapy. The data were presented today as a late breaker oral presentation at Digestive Disease Week 2013 in Orlando, Florida based on abstract number 869b, "Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon-Based Therapy: Results From PROMISE, a Phase III Trial."

"Hepatitis C is a complex disease and physicians need multiple treatment options to provide their patients the best possible chance at successful therapy," said Eric Lawitz , M.D., professor of medicine at University of Texas Health Science Center, Vice President, scientific and research development, The Texas Liver Institute and principal investigator of the PROMISE trial. "I'm pleased that the primary efficacy and safety results from the PROMISE study of simeprevir show sustained virologic response in patients who had relapsed following previous treatment with interferon-based regimens."

In PROMISE, patients we
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor
2. Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
3. Healthscope to commercially launch Circadians Cancers of Unknown Primary Diagnostic Test
4. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
5. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
6. Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
7. MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
8. GeneTex, Inc. to Launch a New Primary Antibody against HIF1a
9. Albireo Has Been Granted Orphan Drug Designation for A4250 from the US FDA for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and for Primary Biliary Cirrhosis (PBC)
10. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
11. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 20, 2014  The acceptance of two ... AAGL Global Congress demonstrates continued interest in the ... provide bowel control. One of the abstracts, presented by ... Division Chief of Urogynecology and Reconstructive Pelvic Surgery ... Award for Best Written Abstract on Urogynecology/Pelvic Floor ...
(Date:11/21/2014)... -- Oxis International, Inc. (OXIS) (OXI.PA) announced today the resignation ... J. Cataldo as Chief Executive Officer, and Steven ... Ken Eaton resigned his positions as Chief Executive ... International, Inc. to pursue new opportunities. Mr. ... of Oxis International, Inc. Mr. Cataldo will continue to serve ...
(Date:11/18/2014)... 18, 2014  NxStage ® Medical Inc. ... of innovative dialysis products , today announced ... dialyzer for the in-center, hemodialysis market.  Streamline Express ... designed to reduce the amount of labor required ... of touch point contamination sites.  The dialyzer enables ...
Breaking Medicine Technology:LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3NxStage Launches New Streamline Express Dialyzer With Pre-attached Blood Tubing Set 2
... with its Investor Day being held tomorrow in New York ... forward-looking earnings expectations for the fourth quarter of Fiscal Year ... for Fiscal Year 2013.  The Company reconfirmed ... and for all of Fiscal Year 2012, as issued in ...
... hospitals handed a resolute vote of confidence over ... enterprise clinical and financial system. Healthmark Regional Medical ... Kit Carson Memorial Hospital plan on leveraging the ... meeting the meaningful use requirements associated with the ...
Cached Medicine Technology:PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day 2PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day 3PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day 4Hospitals Across the Country Select Prognosis HIS Enterprise Clinical and Financial System 2Hospitals Across the Country Select Prognosis HIS Enterprise Clinical and Financial System 3
(Date:11/22/2014)... wide variety and complexity of foods served at holiday ... allergies, an expert warns. "Every person is different ... that it can be really difficult to avoid all ... allergy and clinical immunology at Wake Forest Baptist Medical ... you know you have food allergies, caution should overrule ...
(Date:11/22/2014)... 22, 2014 Hastings and Hastings, a ... experience announces providing clients with the option of leaving ... clients a flexible, intuitive and easy to navigate website ... access to Google + allows clients to research the ... a more informed decision when retaining an attorney. Those ...
(Date:11/22/2014)... 2014 Sandbridge Capital, a private ... the consumer brand sector, acquired a minority stake ... used to help fund BackJoy’s global growth and ... its proprietary apparel and footwear lines. Sandbridge Capital ... of Directors. , BackJoy is a high-growth health ...
(Date:11/22/2014)... November 22, 2014 Wright & Schulte ... side-effects lawsuits have been scheduled between October 2016 ... District of Illinois. U.S. District Judge Matthew F. Kennelly, ... Case Management Order (CMO) on November 6, 2014 that ... attorneys to submit documents and other activities in preparation ...
(Date:11/22/2014)... Those air-blown hand dryers in public restrooms may spread ... study suggests. British researchers placed a harmless type ... to simulate poorly washed hands. They then had them ... to dry their hands. The investigators measured airborne ... both types of dryers than around towel dispensers. ...
Breaking Medicine News(10 mins):Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4Health News:Restroom Hand Dryers Spread More Germs Than Paper Towels, Study Finds 2
... PepsiCo (NYSE: PEP ), the world,s second-largest food and beverage company, today announced new global goals in the areas of nutrition, the environment, and workplace practices at ... ... ... ...
... 22 Accident claims solicitors, First Personal Injury, want to see more advice made readily available to parents and pupils about asbestos exposure ... reasons. , ... , , ... ...
... , March 22 InterAction joins other U.S.-based non-governmental organizations (NGOs) in calling for ... sanitation and hygiene (WASH) crisis. World Water Day provides us with an opportunity to ... safe drinking water and basic sanitation. , ... ...
... For Epilepsy Awareness , ... , ... ... NEW YORK , March 22 This week, bakeries across the United States are cooking ...
... ... on-premise and SaaS archiving provider in the market to archive and stub for all ... archiving for all Unix/Linux-based email servers and file servers for NTFS/NFS/NDS/Netware, , ... Salt Lake City, Utah, and ...
... today by Thomson Reuters. The year-over-year increase topped the 2008 rate of 6.1 percent and occurred in a year when the U.S. inflation rate was negative.   , ... , ... ... ...
Cached Medicine News:Health News:PepsiCo Unveils Global Nutrition, Environment and Workplace Goals 2Health News:PepsiCo Unveils Global Nutrition, Environment and Workplace Goals 3Health News:PepsiCo Unveils Global Nutrition, Environment and Workplace Goals 4Health News:PepsiCo Unveils Global Nutrition, Environment and Workplace Goals 5Health News:PepsiCo Unveils Global Nutrition, Environment and Workplace Goals 6Health News:PepsiCo Unveils Global Nutrition, Environment and Workplace Goals 7Health News:First Personal Injury on Asbestos in Schools 2Health News:Global Development Successes Depend on Access to Water 2Health News:Global Development Successes Depend on Access to Water 3Health News:Purple Cupcake Production on the Rise Nationwide 2Health News:Purple Cupcake Production on the Rise Nationwide 3Health News:MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010 2Health News:MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010 3Health News:MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010 4Health News:MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010 5Health News:MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010 6Health News:Employer Healthcare Costs Jump 7.3% in 2009, According to Thomson Reuters Study 2Health News:Employer Healthcare Costs Jump 7.3% in 2009, According to Thomson Reuters Study 3
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
The Trident ceramic acetabular system provides several important benefits and meets greater demands of younger, more active patients....
Optimal solution for normal acetabulum and younger patients....
Medicine Products: